Stuart Poulton Karyopharm Therapeutics Inc. (KPTI) insider trading activity

Stuart Poulton is EVP, Chief Development Officer of Karyopharm Therapeutics Inc.. Currently has a direct ownership of 67,392 shares of KPTI, which is worth approximately $376,047. The most recent transaction as insider was on Oct 15, 2025, when has been sold 39,682 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 67.4K

147.56% 3M change

79.37% 12M change

Total Value Held $376,047

Stuart Poulton Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 15 2025	BUY Grant, award, or other acquisition	-	39,682 Added 37.06%	67,392 Common Stock
Sep 15 2025	SELL Open market or private sale	$2,578 $6.43 p/Share	401 Reduced 1.43%	27,710 Common Stock
Sep 12 2025	BUY Grant, award, or other acquisition	-	888 Added 3.06%	28,111 Common Stock
Jul 29 2025	SELL Open market or private sale	$834 $4.37 p/Share	191 Reduced 0.7%	27,223 Common Stock
Mar 04 2025	SELL Open market or private sale	$22,316 $6.29 p/Share	3,548 Reduced 11.46%	27,414 Common Stock
Feb 28 2025	BUY Grant, award, or other acquisition	-	9,583 Added 23.64%	30,962 Common Stock
Feb 18 2025	SELL Open market or private sale	$3,725 $0.63 p/Share	5,914 Reduced 1.81%	320,714 Common Stock
Jul 30 2024	SELL Open market or private sale	$3,055 $1.06 p/Share	2,883 Reduced 0.87%	326,628 Common Stock
Mar 01 2024	SELL Open market or private sale	$7,386 $1.2 p/Share	6,155 Reduced 1.83%	329,511 Common
Feb 29 2024	SELL Open market or private sale	$19,083 $1.17 p/Share	16,311 Reduced 4.63%	335,666 Common
Feb 28 2024	BUY Grant, award, or other acquisition	-	188,205 Added 34.84%	351,977 Common Stock
Feb 15 2024	SELL Open market or private sale	$8,010 $1.37 p/Share	5,847 Reduced 3.45%	163,772 Common Stock
Jan 24 2024	BUY Grant, award, or other acquisition	-	13,333 Added 7.29%	169,619 Common Stock
Jul 28 2023	SELL Open market or private sale	$4,836 $1.7 p/Share	2,845 Reduced 1.79%	156,286 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	95,000 Added 37.38%	159,131 Common Stock
Feb 15 2023	SELL Open market or private sale	$18,722 $3.19 p/Share	5,869 Reduced 8.38%	64,131 Common Stock

Stuart Poulton

EVP, Chief Development Officer

Newton, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KPTI shares.

Notify only if

Value

Insider Trading

Get notified when an Karyopharm Therapeutics Inc. insider buys or sells KPTI shares.

Notify only if

Operation

Value

Type

News

Receive news related to Karyopharm Therapeutics Inc.

Track Activities on KPTI

Account